$ALXN Headlines Bed Bath, Starz gain; Citizens

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
$ALXN Headlines

Bed Bath, Starz gain; Citizens Financial debuts 3:52 p.m. Sept. 24, 2014 - Sue Chang
S&P 500 ekes out another record close: stock market live blog recap 4:03 p.m. July 24, 2014 - blogs.marketwatch.com
Biotechs beat estimates, but the Street wants more 11:44 a.m. July 24, 2014 - Russ Britt
22 stocks that may be the gems of earnings season 3:12 a.m. July 10, 2014 - blogs.marketwatch.com
Oracle slides on disappointing results; CarMax soars 4:17 p.m. June 20, 2014 - Sue Chang
Alexion rises 1.4%, among biggest S&P 500 gainers 9:32 a.m. June 6, 2014 - Sue Chang
TripAdvisor leads momentum-play rally to lift Nasdaq 3:52 p.m. May 12, 2014 - Sue Chang
Corner drug store may move overseas to save on taxes 6:31 a.m. April 16, 2014 - Al Lewis
Nasdaq pummeled in worst day since 2011 as tech, biotech cave (Stock market live blog recap) 4:53 p.m. April 10, 2014 - blogs.marketwatch.com
TripAdvisor, Tesla sink as momentum plays lose favor 4:36 p.m. April 10, 2014 - Sue Chang
Biotech hammered as ETFs down 5%, while some stocks fall 10% 1:55 p.m. April 10, 2014 - Russ Britt
Tesla, Facebook, Netflix are Monday’s stocks to watch 5:35 a.m. April 7, 2014 - Sue Chang
Facebook, Tesla slide into bear market territory 4:52 p.m. April 4, 2014 - Sue Chang
Investors continue to pour out of biotech holdings 2:43 p.m. April 4, 2014 - Russ Britt
44 stocks on takeover target radar: Morgan Stanley 12:48 p.m. March 25, 2014 - blogs.marketwatch.com
U.S. stocks fall; Nasdaq skids 1.2% 4:41 p.m. March 24, 2014 - Anora Mahmudova
Apple gains on Comcast talk, new iPhone buzz 4:24 p.m. March 24, 2014 - Sue Chang
First Solar, H-P, Symantec are stocks to watch 4:16 p.m. March 21, 2014 - Sue Chang
First Solar extends winning streak; Symantec plunges 3:07 p.m. March 21, 2014 - Sue Chang
From every angle, technicals point to richer stocks 2:26 p.m. March 11, 2014 - The Trading Deck


5 Orphan Drug Biotech Stocks to Buy With Big Upside Potential 7:41 a.m. Today - 247WallSt.com
Biotech Stock Roundup: Auxilium an Acquisition Target, Amgen Submits another BLA - Analyst Blog 11:05 a.m. Sept. 24, 2014 - Zacks.com
Alexion Pharmaceuticals, Inc. (ALXN): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report 8:00 a.m. Sept. 23, 2014 - Zacks.com
Is Illumina (ILMN) Worth Adding to Your Portfolio? - Analyst Blog 3:20 p.m. Sept. 22, 2014 - Zacks.com
IBD 50 Stocks Setting Up, Including These 5 Medicals 5:35 p.m. Sept. 19, 2014 - Investors Business Daily
Encouraging Phase 2 results for Alexion's asfotase alfa 7:42 a.m. Sept. 19, 2014 - Seeking Alpha
SNN, ALXN And ACT, 3 Health Care Stocks Pushing The Sector Lower 1:04 p.m. Sept. 17, 2014 - TheStreet.com
Stock Market News for September 17, 2014 - Market News 10:10 a.m. Sept. 17, 2014 - Zacks.com
If Achillion's Hep C Nucleotide Isn't Best In Class, The Stock Is Worth Low Single Digits 8:00 a.m. Sept. 16, 2014 - Seeking Alpha
3 Hot Ways to Play the Biotechnology Bonanza 6:36 a.m. Sept. 16, 2014 - InvestorPlace.com
Biotech Stocks With Upside Target Ebola, Liver Disease 6:30 a.m. Sept. 16, 2014 - InvestorPlace.com
Is Intercept Pharmaceuticals Building The Next Great Specialty Franchise? 2:30 p.m. Sept. 15, 2014 - Seeking Alpha
Stock Market News for September 11, 2014 - Market News 10:10 a.m. Sept. 11, 2014 - Zacks.com
Trading Guidelines for Amgen, Biogen Idec, Gilead, 3 Other Biotechs 10:02 a.m. Sept. 11, 2014 - TheStreet.com
Short Sellers Remain Vigilant Against Biotechs 9:45 a.m. Sept. 11, 2014 - 247WallSt.com
Alexion's Asfotase Alfa Gets Japanese Orphan Drug Status - Analyst Blog 5:30 p.m. Sept. 9, 2014 - Zacks.com
SunTrust Robinson Humphrey Starts Coverage on 5 Top Biotech Stocks 8:58 a.m. Sept. 8, 2014 - 247WallSt.com
Japanese regulators tag asfotase alfa an orphan drug for rare bone disorder 7:06 a.m. Sept. 8, 2014 - Seeking Alpha
Alexion Pharmaceuticals: FDA Findings An Easy Fix 5:45 p.m. Sept. 5, 2014 - Investors Business Daily
Insider Trading Alert - BRCM, ALXN And JLL Traded By Insiders 12:03 p.m. Sept. 5, 2014 - TheStreet.com


Paediatric Patients with Hypophosphatasia Receiving Investigational Asfotase Alfa Had Sustained Improvements in Growth and Physical Function 4:49 a.m. Sept. 19, 2014 - BusinessWire - BZX
Alexion Strengthens and Broadens Its Executive Leadership Team 7:30 a.m. Sept. 17, 2014 - BusinessWire - BZX
Improved Survival Observed in Pediatric Patients with Severe Hypophosphatasia (HPP) Who Were Treated with Investigational Asfotase Alfa for Up to Five Years 5:30 p.m. Sept. 14, 2014 - BusinessWire - BZX
NICE Recommends Commissioning of Eculizumab (Soliris®) for All Patients with aHUS in England 7:01 p.m. Sept. 3, 2014 - BusinessWire - BZX
Technical Updates, Upcoming Conferences, Drug Trials, and Acquisition Updates - Research Reports on SL Green, Allstate, HCA Holdings, Alexion and Salix 9:15 a.m. Sept. 3, 2014 - PR Newswire - PRF
Alexion to Present at Investor Conferences 10:00 a.m. Aug. 28, 2014 - BusinessWire - BZX
Collaborations, Upcoming Seminar, Clinical Trial Results, Data Presentation Schedule - Research Reports on AstraZeneca, Illumina, Novartis, Lilly and Alexion 8:30 a.m. Aug. 26, 2014 - PR Newswire - PRF
Alexion Initiates Multinational Registration Trial of Eculizumab for the Prevention of Delayed Graft Function (DGF) after Kidney Transplantation 6:30 a.m. Aug. 25, 2014 - BusinessWire - BZX
Technical Updates, Study Outcomes, Project Approvals, and Quarterly Performance Reviews - Research Reports on Alexion, Novartis, CB&I, L-3 and Emerson 8:40 a.m. Aug. 15, 2014 - PR Newswire - PRF
Researchers to Present New Data on Asfotase Alfa in Pediatric Patients with Hypophosphatasia at the American Society for Bone and Mineral Research 2014 Annual Meeting 4:57 p.m. Aug. 13, 2014 - BusinessWire - BZX
Cannabis Should Be Treated as an Agricultural Commodity, Not a Biotech Investment 2:44 p.m. Aug. 11, 2014 - ACCESSWIRE
Biotech Equities Technical Momentum -- InterMune, Biogen Idec, Insmed, Dendreon, and Alexion Pharma 8:40 a.m. Aug. 11, 2014 - PR Newswire - PRF
Financial Results, FDA Approvals, Orphan Drug Designations, and Certificates - Research Reports on Idenix, Baxter, Alexion, Alere and Zoetis 9:10 a.m. Aug. 7, 2014 - PR Newswire - PRF
European Commission Grants Orphan Drug Designation to Soliris® (eculizumab) for the Treatment of Patients with Myasthenia Gravis (MG) 6:30 a.m. Aug. 1, 2014 - BusinessWire - BZX
Biotech Companies Release Quarterly Financials and Announce Earnings Release Dates - Research Reports on Illumina, Alexion, Questcor, Jazz Pharmaceuticals and Exelixis 8:40 a.m. July 29, 2014 - PR Newswire - PRF
European Medicines Agency Accepts Marketing Authorization Application for Asfotase Alfa as a Treatment for Patients with Hypophosphatasia 6:15 a.m. July 24, 2014 - BusinessWire - BZX
Leadership Appointments, Earnings Conference Calls, Milestone Payments, and Technical Updates - Analyst Notes on Illumina, Alexion, Incyte, Clovis and Keryx 8:10 a.m. July 17, 2014 - PR Newswire - PRF
Alexion Announces the Appointments of David R. Brennan, M. Michele Burns and Christopher J. Coughlin to Its Board of Directors 8:02 a.m. July 16, 2014 - BusinessWire - BZX
Alexion Pharmaceuticals to Report Second Quarter 2014 Results on Thursday, July 24, 2014 10:00 a.m. July 10, 2014 - BusinessWire - BZX
Market Activity and Upcoming Quarterly Results - Analyst Notes on Bristol-Myers Squibb, Abbott, Alexion, Mallinckrodt and Baxter 6:10 a.m. July 8, 2014 - PR Newswire - PRF

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Gildan Faces Class Action Deadline Over Fraud Claims

Updated Category News Views 74

Gildan's Legal Storm: Fraud Allegations When news hits about a big player like Gildan Activewear (NYSE: GIL) facing a class-action lawsuit, it's like a thunderstorm for investors who traded their stocks between February 19, 2025, and June 15, 2026. This lawsuit alleges what we some might call classic financial engineering—channel stuffing to be precise—that’s got...

Continue Reading
Why Accurate HVAC Load Calculations Matter

Updated Category News Views 205

Beyond Square Footage: Critical HVAC Considerations When it comes to heating and cooling your home, simply considering its square footage is like trying to predict the weather with nothing but a coin flip. Bob Schmid, an HVAC guru from Ocean View, NJ, pulls back the curtain on why the details really matter in determining the most efficient and effective HVAC setup for any...

Continue Reading
Context Labs Unveils AI Distillery for Enterprises

Updated Category News Views 517

Rethinking AI with Sovereignty in Mind A bouquet of tech buzzwords lands on every investor's doorstep with the unveiling of Context Labs' latest contraption. We’re talking about the AI Distillery™, which promises enterprises a way to run sovereign AI systems by keeping data in-house. Now, if you’re nodding along to the buzz, let's cut through the clutter....

Continue Reading
Smart Salary Moves for S Corp Owners: Riggs Unpacks Insights

Updated Category News Views 197

Decoding the S Corp Salary Dance How much salary should the savvy owners of S corporations draw? It ain't a simple task or one-size-fits-all deal, folks. David Riggs spills the beans on HelloNation, sharing insights on this complex tango between drawing wages and raking in shareholder distributions. In the end, it’s about playing by the IRS rules—or risking a penalty...

Continue Reading
Baystate Health Expands: A New Chapter with Mercy

Updated Category News Views 121

Baystate Health Moves Forward with Strategic Integration Well, here's a tale that's as much about legacy as it is about progress. Baystate Health has brought Baystate Mercy Hospital into its fold, blending history with future prospects. This integration, folks, isn't just a merger—it's a downright overhaul of how healthcare operates in Western Massachusetts. We’re...

Continue Reading
Home Genius Exteriors Expands with Five New Locations

Updated Category News Views 125

Pushing Beyond the Backyard: Home Genius Opens New Doors Hold onto your hats, folks. Home Genius Exteriors is making a splashy move by setting up shop in five new points across the map. We're talking Toledo, Ohio; Nashville, Tennessee; Lehigh Valley and Erie in Pennsylvania; and Dover, Delaware. That's quite a leap from their cozy base of operations, marking a clear push...

Continue Reading
Bahrain's USD 3.89 Billion Investment Surge in 2026

Updated Category News Views 187

Bahrain's Bold Moves to Woo Global Investment Bahrain's never been one to tiptoe around, huh? With a whopping USD 3.89 billion on the line, the Kingdom's flashing its neon sign to investors: "Open for Business!" These Golden License projects aren't just a few shiny new ventures — they're bridging aviation logistics, real estate, and the tech sector. Talk about ambition....

Continue Reading
Decoding Real Estate Value: A Market Insider's Take

Updated Category News Views 270

Riding the Waves of Real Estate Pricing Homeowners dipping their toes into the real estate market know that setting the right price ain't a walk in the park. Luckily, Matt Nuzie, Shelton's real estate pro, has peeled back the layers on comparative market analyses (CMA) in a HelloNation piece. This isn't just about tossing a number out there—it's about understanding the...

Continue Reading
Ensuring Flooring Stability: Acclimation's Key Role

Updated Category News Views 191

Dive into the World of Flooring Acclimation You ever hear about flooring acclimation? Sounds as riveting as watching paint dry, right? But Austin J. Messina from Salem, New Hampshire, is here to tell us it's the secret to flooring that doesn't buckle under pressure—literally. Messina's insights, splashed across the pages of HelloNation, delve deep into the nitty-gritty...

Continue Reading
XPeng Hits New Monthly Delivery Record in October

Updated Category News Views 247

XPeng Smashes Delivery Records Yet Again Ah, the green light’s on for XPeng, and it's a bright one! This October, we learned that XPeng hit the throttle hard with a new record of 50,237 vehicles delivered. Now, that's a sizable rally—a 22% climb month-over-month and shooting 20% higher than last October. For a company like XPeng, which resembles a bulldog with its...

Continue Reading

Top 5 Most Recently Viewed Articles

Medicenna's MDNA11 Progress and Insights from ABILITY-1 Study

Updated Category News Views 124

Overview of Medicenna Therapeutics Medicenna Therapeutics Corp. is a dynamic player in the clinical-stage immunotherapy arena, particularly noted for their innovative developments centered around Superkines. Their focus on creating next-generation therapeutic options has positioned them as a notable entity in the fight against cancer. Recently, the company announced the...

Continue Reading
Important Class Action Update for PACS Group Investors

Updated Category News Views 266

Key Information for PACS Group Investors Faruqi & Faruqi, LLP is actively reaching out to investors impacted by their investment in PACS Group. If you've faced losses exceeding $50,000, it's crucial to consider your legal options. The firm is encouraging investors to connect with Josh Wilson, a partner at the firm, for clarification of rights and options. PACS Group is...

Continue Reading
Stock Market Fluctuations: Key Players and Recent Performances

Updated Category News Views 134

Market Updates and Performance Overview The U.S. stock market showcased a mix of performances as trading commenced recently. The Dow Jones index experienced a slight decline of approximately 0.1% amidst varying trends across other indices. Sector Analysis As trading opened, the Dow was recorded at 48,698.11, reflecting a 0.07% drop, whereas the NASDAQ showed signs of...

Continue Reading
Signal Rock Capital Launches Investment Strategy for Growth

Updated Category News Views 360

Signal Rock Capital Launches New Investment Venture Signal Rock Capital, a new private investment firm, is making waves in the investment world by focusing on lower middle-market businesses. The firm, co-founded by passionate investors, aims to partner with innovative, founder-led companies that operate in often overlooked sectors of the economy. Investment Focus and...

Continue Reading
Microsoft's Dividend Boost and Buyback Strategy Leads to Growth

Updated Category News Views 135

Microsoft's Strategic Financial Moves Recently, Microsoft Corporation (NASDAQ: MSFT) made waves by announcing a significant increase in its quarterly dividend and a new share repurchase program. Following the news, Deutsche Bank reaffirmed its Buy rating on Microsoft’s stock and set a price target of $475. This move to raise the dividend by 10.7%, from $0.75 to $0.83...

Continue Reading